AZD-1480
Product Sizes
50 mg
£ POA
HY-10193-50MG
100 mg
£ POA
HY-10193-100MG
10 mg
£ POA
HY-10193-10MG
200 mg
£ POA
HY-10193-200MG
5 mg
£ POA
HY-10193-5MG
25 mg
£ POA
HY-10193-25MG
10mM/1mL
£ POA
HY-10193-10MM
About this Product
- SKU:
- HY-10193
- CAS Number:
- 935666-88-9
- Extra Details:
- AZD-1480 is an ATP-competitive inhibitor of JAK1 and JAK2 with IC50s of 1.3 nM and [1].
- Molecular Weight:
- 348.77
- Purity:
- 99.74
- References:
- [1]Derenzini E, et al. The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma. Blood Cancer J. 2011 Dec;1(12):e46.|[2]Scuto A, et al. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia. 2011 Mar;25(3):538-50.|[3]McFarland BC, et al. Therapeutic potential of AZD1480 for the treatment of human glioblastoma. Mol Cancer Ther. 2011 Dec;10(12):2384-93.|[4]Xin H, et al. Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. Cancer Res. 2011 Nov 1;71(21):6601-10.|[5]Hedvat M, et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell. 2009 Dec 8;16(6):487-9|[6]Ni J, et al. Tyrosine receptor kinase B is a drug target in astrocytomas. Neuro Oncol. 2017 Jan;19(1):22-30.
- Research Area:
- Cancer
- Shipping Conditions:
- Ambient
- Storage Conditions:
- -20[o]C; 3 years; 4[o]C; 2 years (Powder)
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Small Molecules
- Pathway:
- Epigenetics;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt
